Tercica shareholder approval leads to merger with Ipsen

By Lisa Kerner

Charlotte, N.C., Oct. 17 - Tercica, Inc. stockholders voted to approve the adoption of the agreement and plan of merger with Beaufour Ipsen Pharma at a special meeting on Thursday.

The merger was then completed with an Ipsen subsidiary merging with and into Tercica.

Tercica remains the surviving corporation as a wholly owned subsidiary of Ipsen, according to a form 8-K filed with the Securities and Exchange Commission.

The process to delist Tercica from the Nasdaq Global Market and to deregister Tercica's common stock has also begun.

In June it was reported that Tercica agreed to be acquired by Ipsen, SA for $9.00 per share in cash or a total of $663 million.

Tercica is a Brisbane, Calif., biopharmaceutical company, and Ipsen is a specialty pharmaceutical group based in Paris.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.